Beverley has extensive biopharma business development experience. Her most recent position was at Amphista Therapeutics, where she served as Interim Chief Executive Officer and previously as Chief Business and Operating Officer, leading a strategic review of the business, and executing two major partnerships. Before joining Amphista, Beverley’s career spanned over a decade at GSK and she has held senior roles at other leading biotechnology companies, including Cambridge Antibody Technology prior to its acquisition by AstraZeneca.
She holds an MA in Chemistry and a DPhil in Organic Chemistry from the University of Oxford, and an MBA from the University of Cambridge.
